Hamburg, Germany | Abingdon, UK - Evotec OAI, Hamburg, Germany (EVOTEC BioSystems AG, Neuer Markt: EVT) a supplier of high value added biological, chemical and screening services, has signed a one-year contract to supply chemical compound libraries and associated data to Roche, of Basel, Switzerland.
The compounds will be used by Roche in their drug discovery screening programmes.
Dr Edwin Moses, President of Evotec OAI, said:
"We are very pleased to have secured this contract with Roche, one of the world's leading research-oriented healthcare companies, to supply libraries to support their screening programmes. We have worked with Roche before on similar projects and look forward to this, enjoyable partnership and are confident that through our expertise in this area we can add significant value to their drug discovery programmes."
Dr Dave Brown, Roche's Global Head of Chemistry and Head of Pre-clinical R&D at Roche, Welwyn, UK, added:
"We're very pleased to be working with Evotec OAI, a company with a well-established reputation as a provider of chemistry and biology services and a good corporate partner. This Alliance extends Roche's commitment to building a world-class compound library for random and focused screening."
Notes for editors:
Headquartered in Basel, Switzerland, Roche is one of the world's leading research-oriented healthcare groups in the fields of pharmaceuticals, diagnostics and vitamins. Roche's innovative products and services address needs for the prevention, diagnosis and treatment of disease, thus enhancing people's well-being and quality of life. The Group has approximately 65,000 employees and sells its products in over 170 countries.
Research at Roche focuses on significant unmet medical needs in the management of diseases of the central nervous system and genitourinary tract, metabolic disorders, inflammation, bone diseases, cancer, vascular diseases and virology.
Evotec OAI offers the full range of high-value added products and services required to discover and develop drugs more effectively and efficiently. By integrating accelerated methods in biology, chemistry and screening, the Company has established a unique position as a 'one-stop-shop' for all the critical elements in the drug discovery research and development process from target to clinical development. Approximately 500 people are based in Hamburg, Germany and Abingdon, UK Evotec OAI already has close links with many of the leading companies in the pharmaceutical and biotechnology industries, including Novartis, Pfizer, GlaxoSmithKline, Aventis, Pharmacia/Sugen, Eli Lilly, Bayer, BMS, Roche, Amgen, Biogen, Vertex, Serono and Immunex. Evotec OAI's shares are listed on the Neuer Markt of the
Frankfurt Stock Exchange.